# Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

> **NCT00252005** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 520 (—)

## Conditions studied

- Deep-Vein Thrombosis

## Interventions

- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT00252005
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 520 (—)
- **Last updated:** 2010-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00252005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00252005, "Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00252005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*